Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

TAKTakedaFinished

A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

5Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • 2 insiders sold shares within a month

    Since Nov 4, 2026 · was worth 5, fading over time

    +4.9
Worry score5

Score over time

Stage
Phase 1/2
Patients
324 (final count)
Started
Jun 16, 2016
Main results expected
Sep 29, 2026
Fully finished
Sep 29, 2026
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Part 1, Dose Escalation Component: Recommended Phase 2 Dose (RP2D) of Orally Administered TAK-788

    Measured over: Cycle 1 (Cycle length is equal to [=] 28 days)

  • Part 2, Expansion Cohorts 1, 2, 4, 5 and 7: Confirmed Objective Response Rate (ORR) Assessed by the Investigator

    Measured over: Up to 36 months after first dose

  • Part 2, Expansion Cohort 3: Intracranial ORR (iORR) Assessed by Independent Review Committee (IRC)

    Measured over: Up to 36 months after first dose

  • Part 2, Expansion Cohort 6: Confirmed ORR Assessed by IRC

    Measured over: Up to 36 months after first dose

  • Part 3, Extension Cohort: Confirmed ORR Assessed by IRC

    Measured over: Up to 36 months after first dose

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • insider_selling_cluster: base 5, now 4.9, since 2026-11-04, fades (half-life)

Raw record changes

  • none yet

Trial ID NCT02716116 · record last updated 2026-10-28 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT02716116) ↗